ClinicalTrials.gg
Active, not recruitingNCT04110327HEALUpdated Jun 29, 2026

An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease

An observational study in Peripheral Arterial Disease and Critical Lower Limb Ischemia, sponsored by Micro Medical Solution, Inc.. Active, not recruiting at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Micro Medical Solution, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Peripheral Arterial Disease with a site in Belgium — 8 open to participants now, 17 under way, 3 of them phase 3. Peripheral Arterial Disease · Belgium.

Planned enrollment
14th of 27
300 · median 300
Started
2019
with 2 others
Observational
27 of 85
4 open now
Primary completion
2026-12
later than 9 of 16 live
Registered
65th of 85
by date

Among the 85 studies in Peripheral Arterial Disease with a site in Belgium, this one is the 14th largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2019, is one of 27 observational ones, reaches primary completion later than 9 of the 16 other live ones, and was the 65th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

8 of the 85 studies in Peripheral Arterial Disease with a site in Belgium are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Peripheral Arterial Disease with a site in Belgium, or all of them as a file.
02

Study summary

Non-randomized, multicenter, combined prospective and retrospective cohort analysis consisting of a single arm treated with the MicroStent™ System.

Read the detailed description

Subjects with peripheral arterial disease (PAD) whom the investigator has treated or intends to treat with the MicroStent™ System per the current instructions for use (IFU), and who have given written informed consent, will be enrolled in this study. Up to 300 subjects will be enrolled:

The objective of this post market registry is to evaluate procedural and long-term clinical outcomes for subjects undergoing intervention with the MicroStent® System for treatment of lower extremity peripheral arterial disease (PAD), presenting with below-the-knee lesions.

03

Conditions studied

  • Peripheral Arterial Disease
  • Critical Lower Limb Ischemia

Keywords

  • MicroStent
  • Below the Knee
  • CLI
  • Below the Ankle
  • CLTI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include any subject with symptomatic peripheral arterial disease (PAD) that require intervention with the MicroStent™ System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any subject with below the knee, at the ankle level or below the ankle peripheral arterial lesions previously treated or intended to be treated with the MicroStent® System per the current indications for use
  2. For across the ankle joint intervention, distal runoff to digital branches or arcuate arteries must be present on angiography prior to MicroStent deployment
  3. Subject's age is ≥ 18 years.
  4. Subject must be willing to sign a patient form.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or planning to become pregnant during the study duration
  2. Subject has a of less than one (1) year
  3. Subject has a known allergy to concomitant medication, contrast agents (that cannot be medically managed), anti-, anti-coagulant or thrombolytic medications
  4. Subject is enrolled in another study that has not reached its primary endpoint at the time of enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • DeviceMicroStent

    Treatment of arterial stenosis or occlusion with the MicroStent Peripheral Vascular Stent System

06

What researchers measure

Primary outcomes

  1. Primary Patency

    Freedom from target lesion occlusion with no clinically driven target lesion revascularization (TLR)

    Time frame: 6 months post-procedure

  2. Freedom from Perioperative Death and Major Adverse Limb Events (MALE)

    Freedom from all-cause death or major adverse limb events. Major adverse limb events include above-ankle amputation, new bypass graft or graft revision, and thrombectomy or thrombolysis involving the target lesion.

    Time frame: 30 days post-procedure

Secondary outcomes

  1. Freedom from Major Adverse Limb Events

    Major adverse limb events include above-ankle amputation, new bypass graft or graft revision, and thrombectomy or thrombolysis involving the target lesion.

    Time frame: 6, 12, 24 Months

  2. Freedom from Major Amputation

    Freedom from above-ankle amputation in the target limb

    Time frame: 6, 12, 24 Months

  3. Freedom from Clinically Driven Target Lesion Revascularization (TLR)

    Freedom from any revascularization procedure with involvement of the target lesion that is due to complaints of leg pain or worsening leg pain, a progressing, non-healing ulcer, or new ulcer formation with or without the presence of an abnormal non-invasive test.

    Time frame: 6, 12, 24 Months

  4. Wound Healing

    Wounds will be identified at the baseline visit and classified as fully healed or not healed at each follow up visit.

    Time frame: 30 days, 6, 12, 24 Months

  5. Device Success

    Operator assessment of successful device deployment and full coverage of the lesion as intended

    Time frame: Procedure

  6. Technical Success

    Attainment of less than or equal to 30% residual stenosis by visual estimate in the treated lesion using only the study device according to the IFU (i.e. including post dilation at the discretion of the investigator)

    Time frame: Procedure

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 86 months is above that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2019
First posted
Oct 1, 2019
StartActual
Oct 31, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04110327
Lead sponsor
Micro Medical Solution, Inc.
Responsible party
Sponsor
First posted
Oct 1, 2019
Start date
Oct 31, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion